

# 1     **The lower-airway microbiome and metabolome in preterm infants: Identifying** 2             **potential predictive biomarkers of bronchopulmonary dysplasia**

3     **Qi Xu<sup>2</sup>, Jialin Yu<sup>1\*</sup>, Junli He<sup>1, 3</sup>, Yu He<sup>3</sup>,**

4     <sup>1</sup>Department of Neonatology, Shenzhen University General Hospital, Shenzhen,  
5     China

6     <sup>2</sup>Children's Hospital, Capital Institute of Pediatrics, Beijing, China

7     <sup>3</sup>Department of Neonatology, Children's Hospital of Chongqing Medical University,  
8     Chongqing, China

9

10    Correspondence: Jialin Yu

11    Email address: yujialin486@126.com

12    Post address: No. 1098, Xueyuan Avenue, Xili University Town, Shenzhen, China

13

## 14    **Abstract**

15       The lower-airway microbiome may influence the pathogenesis of lung disease.  
16    Bronchopulmonary dysplasia (BPD) is a serious morbidity associated with preterm  
17    birth that may be influenced by lower-airway microbial or metabolic alterations. This  
18    study used 16S rRNA gene sequencing, metabolomic analyses, and the Kyoto  
19    Encyclopedia of Genes and Genomes (KEGG) database to investigate the  
20    lower-airway microbiome and metabolome in a cohort of preterm infants with mild,  
21    moderate, or severe BPD or no BPD. Differences in the diversity and composition of  
22    the infants' lower airway microbiota, as well as metabolic status, were initially  
23    observed, but became less pronounced at 7 days of life. Decreased diversity of the  
24    lower-airway microbiome, increased abundance of *Stenotrophomonas*, and increased  
25    level of sn-glycerol 3-phosphoethanolamine were associated with increased BPD  
26    severity, and have potential as predictive biomarkers for BPD. *Stenotrophomonas* may  
27    contribute to the development of BPD and influence the composition of the  
28    lower-airway microbiome through its metabolite, sn-glycerol 3-phosphoethanolamine.  
29    These findings provide novel insights into the lower-airway microbiome and its role  
30    in BPD.

# **The lower-airway microbiome and metabolome in preterm infants: Identifying potential predictive biomarkers of bronchopulmonary dysplasia**

**Qi Xu<sup>2</sup>, Jialin Yu<sup>1\*</sup>, Junli He<sup>1</sup>, Qi Tan<sup>3</sup>, Yu He<sup>3</sup>,**

<sup>1</sup>Department of Neonatology, Shenzhen University General Hospital, Shenzhen, China

<sup>2</sup>Children's Hospital, Capital Institute of Pediatrics, Beijing

<sup>3</sup>Department of Neonatology, Children's Hospital of Chongqing Medical University, Chongqing, China

## **Abstract**

The lower-airway microbiome may influence the pathogenesis of lung disease. Bronchopulmonary dysplasia (BPD) is a serious morbidity associated with preterm birth that may be influenced by lower-airway microbial or metabolic alterations. This study used 16S rRNA gene sequencing, metabolomic analyses, and the Kyoto Encyclopedia of Genes and Genomes (KEGG) database to investigate the lower-airway microbiome and metabolome in a cohort of preterm infants with mild, moderate, or severe BPD or no BPD. Differences in the diversity and composition of the infants' lower airway microbiota, as well as metabolic status, were initially observed, but became less pronounced at 7 days of life. Decreased diversity of the lower-airway microbiome, increased abundance of *Stenotrophomonas*, and increased level of sn-glycerol 3-phosphoethanolamine were associated with increased BPD severity, and have potential as predictive biomarkers for BPD. *Stenotrophomonas* may contribute to the development of BPD and influence the composition of the lower-airway microbiome through its metabolite, sn-glycerol 3-phosphoethanolamine. These findings provide novel insights into the lower-airway microbiome and its role in BPD.

**Key words:** BPD, microbiome, genomics, metabonomic

## 61 **1. Introduction**

62       Bronchopulmonary dysplasia (BPD) is a serious morbidity associated with  
63 preterm birth that affects an estimated 50% of infants born at < 28 weeks of gestation  
64 [1]. Infants with BPD have an increased risk of mortality during the first year. Those  
65 who survive may suffer long-term pulmonary impairment and abnormal  
66 neurodevelopment, which can result in substantial healthcare resource utilization and  
67 cost [2]. Risk factors for BPD include, but are not limited to, gestational age at birth,  
68 impaired growth for gestational age, low infant birth weight, infectious exposures,  
69 barotrauma, oxygen exposure, and environmental cigarette smoke [3].

70       Evidence from epidemiological data, clinical data, and animal models indicate a  
71 key role for the microbiome in lung disease [4-6], and indicate that the lower-airway  
72 microbiome is altered in multiple respiratory disorders [7, 8]. Some reports show that  
73 the lower-airway microbiome is present at birth, and microbial dysbiosis may be  
74 associated with BPD [9, 10]. However, by now the related research is rare and the  
75 present results differ from each other, so it needs further research. What's more, the  
76 mechanisms by which the microbiome alterations lead to BPD have never been  
77 addressed. Gut microbiota is associated with a variety of human diseases through  
78 metabolites [11]. We hypothesized that lower-airway microbial metabolism plays a  
79 role in the pathogenesis of BPD.

80       In this prospective observational cohort study, tracheal aspirates (TA) were  
81 collected during mechanical ventilation of infants to investigate 1) the lower-airway  
82 microbiome at birth (Day 1) and on Day 7 after birth; 2) the lower-airway  
83 metabolomic signatures at birth and on Day 7 after birth; and 3) the relationship  
84 between differential metabolites and specific bacteria among infants with severe BPD,  
85 moderate BPD, mild BPD, and no BPD.

## 87 **2. Methods**

88       This prospective observational cohort study was conducted at the Neonatal  
89 Intensive Care Unit of the Children's Hospital of Chongqing Medical University  
90 between October 2017 and July 2018. The Institutional Review Board of Chongqing

Medical University approved the protocol. Informed consent was received from the parents or guardians of all participants. The study was performed in accordance with approved guidelines.

## **2.1 Patient population and clinical data collection**

Infants born at <34 weeks gestation that underwent endotracheal intubation and mechanical ventilation in the first 24 h of life and remained intubated until at least Day 7 after birth were included in this study. Exclusion criteria were: 1) clinical evidence of congenital heart disease (except patent ductus arteriosus [PDA], patent foramen ovale [PFO] or atrial septal defect [ASD] < 1cm, or ventricular septal defect [VSD] < 2mm if known prior to enrollment); 2) lethal congenital abnormality; 3) congenital sepsis; 4) evidence of pulmonary hypoplasia; or 5) futile cases (anticipated death prior to hospital discharge) [10].

Infants were divided into four groups stratified by the diagnosis and severity of BPD: severe BPD, moderate BPD, mild BPD, and no BPD. BPD was diagnosed based on the need for supplemental oxygen at 28 days of age [12, 13]. BPD status and severity was assessed at 36 weeks postmenstrual age according to the National Institutes of Health workshop definition [13]. Late onset sepsis was defined as a positive blood culture after 72 h of life.

Clinical data were collected from a review of electronic medical records at study enrollment and during hospitalization. Information on maternal history, delivery, and clinical assessments was recorded.

## **2.2 Sample collection**

Tracheal aspirates (TA) were collected during mechanical ventilation at birth (Day 1) and on Day 7 after birth according to a previously published protocol [13-15]. Briefly, 0.5 ml of sterile isotonic saline was instilled into the infants' endotracheal tubes. Infants were manually ventilated through their endotracheal tube for three breaths using a bag-mask, and fluid was suctioned into a sterile mucus trap [14]. Samples were divided into 2 aliquots for extraction of bacterial DNA or metabolomics research and frozen at -80°C until further processing.

## 120 **2.3 Isolation of microbial DNA, creation of 16S V4 amplicon library, and DNA** 121 **sequencing**

122 Microbial genomic DNA from each sample was isolated and purified. The V4  
123 region of the 16S rRNA gene from the microbial DNA was amplified using a  
124 polymerase chain reaction (PCR) with unique bar coded primers to create an  
125 “amplicon library” [16]. The library was sequenced using the Illumina MiSeq  
126 platform and subsequently quantified (KAPA Library Quantification Kit KK4824),  
127 according to the manufacturer's instructions.

## 128 **2.4 Profiling of 16S rRNA gene sequencing data**

129 Raw sequences were processed with the Quantitative Insights into Microbial  
130 Ecology (QIIME) 1.8.0 pipeline<sup>1</sup>. The concat function was used to combine reads into  
131 tags according to an overlapping relationship. Reads from each sample were separated  
132 with barcodes, and low quality reads were removed. Processed tags were clustered at  
133 97% similarity into operational taxonomic units (OTUs). Taxonomy was assigned to  
134 OTUs by matching to the Greengenes database (Release 13.8)<sup>2</sup>. Alpha diversity  
135 analyses (Shannon index) and beta diversity analyses (principal coordinate analysis  
136 [PCoA]) were performed.

## 137 **2.4 Metabolomics analysis based on UHPLC-Q-TOF/MS**

138 TA samples were analyzed using an ultra-high-performance liquid  
139 chromatography (UHPLC) system (1290 Infinity LC, Agilent Technologies) coupled  
140 to a quadrupole time-of-flight mass spectrometer (AB Sciex TripleTOF 6600) at  
141 Shanghai Applied Protein Technology Co., Ltd.

142 Samples were thawed at 4°C and 100 µL aliquots were mixed with 400 µL of  
143 cold methanol/acetonitrile (1:1, v/v) to remove the protein. After centrifuging for 15  
144 min (14000g, 4 °C), the supernatant was dried in a vacuum centrifuge. For liquid  
145 chromatography-mass spectrometry (LC-MS), samples were dissolved in 100 µL  
146 acetonitrile/water (1:1, v/v). Pooled quality control (QC) samples were used to  
147 monitor the stability and repeatability of instrument analysis. The QC samples were  
148 inserted regularly and analyzed in every 5 samples.

149 Raw LS electrospray ionization (ESI) MS data were converted into m/z format

150 and analyzed for non-linear retention time (RT) alignment, peak detection, and  
151 filtration.

## 152 **2.5 Profiling of metabolomics data**

153 Processed data were normalized to total peak intensity, imported into SIMCA-P  
154 (version 14.1, Umetrics, Umea, Sweden), and analyzed using Pareto-scaled principal  
155 component analysis (PCA) and orthogonal partial least-squares discriminant analysis  
156 (OPLS-DA). The variable importance in the projection (VIP) value for each variable  
157 in the OPLS-DA model was calculated to indicate its contribution to the classification.  
158 One-way ANOVA was used to determine the significance of each metabolite with a  
159 VIP value >1.  $P < 0.05$  were considered statistically significant. Discriminatory  
160 metabolites within the data set were visualized as heat maps, which were generated  
161 using a hierarchical clustering algorithm. Molecules associated with significant  
162 changes were searched against the Kyoto Encyclopedia of Genes and Genomes  
163 (KEGG) database (<http://www.genome.jp/kegg/pathway.html>).

## 164 **2.6 Statistical analysis**

165 Statistical analysis was performed using SPSS version 22.0 for Windows (SPSS  
166 Inc., USA). Normally distributed data are expressed as mean  $\pm$  SD; non-normally  
167 distributed data are expressed as median and interquartile range (IQR). Between  
168 group differences were analyzed with Fisher's Exact test for categorical variables and  
169 Kruskal-Wallis test for continuous variables after subsampling. Pairwise comparison  
170 was performed with White's non-parametric t-test. Correlations between  
171 microbiome-related metabolites and bacterial species were evaluated using Pearson's  
172 correlation coefficient.  $P < 0.05$  was considered statistically significant.

## 174 **3.0 Results**

### 175 **3.1 Demographic and clinical characteristics of the enrolled patients**

176 This study included 30 premature infants divided into 4 groups, including 10  
177 infants with severe BPD, 5 infants with moderate BPD, 10 infants with mild BPD,  
178 and 5 infants with no BPD. The demographic and clinical characteristics of the  
179 included infants are shown in **Table 1**. There were no significant differences in the

demographic and clinical characteristics between the groups, except for number of hours of mechanical ventilation and number of days of antibiotics.

### 3.2 Diversity and composition of the lower-airway microbiome

The Shannon index was significantly lower at birth (Day 1) ( $P=0.0019$ ; **Figure 1a**) and on Day 7 after birth ( $P=0.016$ ; **Figure 1b**) in infants with BPD compared to no BPD. The difference was more pronounced on Day 1 and was negatively correlated with the severity of BPD. Principal coordinates analysis (PCoA) showed a significant difference in the bacterial composition of the lower-airway microbiome at birth (Day 1) between the four groups (**Figure 1c**), and a less distinct difference on Day 7 after birth (**Figure 1d**).

At the phylum level, *Proteobacteria* was dominant in the lower-airway microbiome of all infants at birth (Day 1) (**Figure 1e**) and on Day 7 after birth (**Figure 1f**), and there were no significant differences in the composition of the lower-airway microbiome between the four groups. At the genus level, the composition of the lower-airway microbiome was significantly different between groups at birth (Day 1). *Stenotrophomonas* was more abundant in infants with BPD compared to no BPD, and abundance was positively correlated with the severity of disease ( $P < 0.05$ ) (**Figure 2a**). Findings on Day 7 after birth were similar, but not statistically significant ( $P=0.064$ ) (**Figure 2b**).

### 3.3 Metabolomic analysis of tracheal aspirates (TA)

TAs were subjected to LC/MS analysis in positive ion mode (ES+) and negative ion mode (ES-).

Principle component analysis (PCA) was performed to reduce dimensionality in the dataset (**Figure 3a, b**). Hierarchical clustering heat maps visualized patterns in molecular data across groups (**Figure 3c-f**). There were significant differences in 63 metabolites, including 23 in ES- and 40 in ES+ (Figure 3c,d ), between the four groups at birth (Day 1), and 29 metabolites, including 11 in ES- and 18 in ES+, on Day 7 after birth (**Figure 3e-f**). Among these metabolites, sn-glycerol 3-phosphoethanolamine was positively correlated with BPD severity at birth (Day 1) (**Figure 4**), but not on Day 7 after birth.

### 210 3.4 Correlation between the lower-airway microbiome and metabolites

211 Pearson's correlation coefficient was used to explore the functional correlation  
212 between the changes in the lower-airway microbiome and differences in metabolites  
213 across the four groups at birth (Day 1) (**Figure 5**). There was a significant positive  
214 correlation between the abundance of *Stenotrophomonas* and sn-glycerol  
215 3-phosphoethanolamine levels ( $r=0.45$ ) ( $P<0.05$ ).

### 217 Discussion

218 Studies investigating the correlation between BPD and the lower-airway  
219 microbiome in infants are scarce, and there remains an unmet clinical need to describe  
220 the lower-airway microbial communities and lower-airway metabolomic signatures in  
221 patients with BPD. Findings will allow the identification of microbial biomarkers for  
222 early detection of BPD and further understanding of the pathophysiology of BPD.

223 The present study used 16S rRNA gene sequencing, metabolomic analyses, and  
224 the KEGG database in attempt to fill these evidence gaps. Results showed that  
225 multiple bacterial taxa can be identified in the respiratory secretions of intubated  
226 premature infants, even at birth and prior to surfactant administration. The diversity  
227 and composition of the lower-airway microbiome in infants with and without BPD  
228 varied at birth, but the differences became less pronounced on Day 7 of life.  
229 Consistent with a previous report, our study showed lower diversity in the  
230 lower-airway microbiome of infants that developed BPD [14]. Our results also  
231 revealed that alpha diversity of lower-airway communities was negatively correlated  
232 with BPD severity. At the phylum level, there were no significant differences in the  
233 composition of the lower-airway microbiome in infants with and without BPD or  
234 according to BPD severity. *Proteobacteria* was the most abundant microbe in all  
235 infants. These data align with one previous report, [14], but differ from another, which  
236 found that *Staphylococcus* and *Ureaplasma* were the most dominate lower-airway  
237 microbes in infants in their institution [10]. These disparate findings may be due to  
238 different environments, which likely influenced the composition of the lower-airway  
239 microbiome. At the genus level, *Stenotrophomonas* was significantly more abundant



240 in infants with BPD compared to no BPD, and the abundance of *Stenotrophomonas*  
241 was positively correlated with BPD severity. These findings suggest that decreased  
242 diversity of the lower-airway microbiome and increased abundance of  
243 *Stenotrophomonas* in the lower-airway microbial community of intubated premature  
244 infants have potential as microbial biomarkers for early detection of BPD.

245 *Stenotrophomonas* is a nosocomial opportunistic pathogen of the  
246 *Xanthomonadaceae* family [17]. *Stenotrophomonas* isolated from the environment or  
247 in the clinical setting exhibits resistance to antibiotics and stress and forms biofilms  
248 on various surfaces, including the abiotic surfaces of catheters and prosthetic devices  
249 [18, 19]. *Stenotrophomonas* colonizes the lungs of patients with cystic fibrosis and  
250 those who are immunocompromised, and may represent a marker of chronic lung  
251 disease [18, 20-22]. *Stenotrophomonas* can influence the spatial organization and thus  
252 the function and composition of complex microbiomes [23, 24]. Data from the present  
253 study suggest a role for *Stenotrophomonas* in the pathogenesis of BPD in intubated  
254 premature infants.

255 As the composition of the lower-airway microbiome in preterm infants varied  
256 with the presence or absence of BPD and with BPD severity, we characterized the  
257 lower-airway metabolome in these infants. Findings showed significant differences  
258 between infants in 63 metabolites at birth (Day 1) and 29 metabolites on Day 7 of life,  
259 implying that metabolite variation paralleled that of the lower-airway microbiome.  
260 Among these metabolites, sn-glycerol 3-phosphoethanolamine was  
261 positively correlated with BPD severity, identifying it as a potential metabolic  
262 biomarker for early detection of BPD. The KEGG database showed that sn-glycerol  
263 3-phosphoethanolamine has a role in glycerophospholipid metabolism.  
264 Glycerophospholipid has structural functions in bacteria, facilitates bacterial  
265 adaptation to environmental conditions, and is involved in bacteria–host interactions  
266 [28]. Glycerophospholipid is also associated with the pathophysiology of chronic  
267 obstructive pulmonary disease (COPD) [29]. These findings suggest that sn-glycerol  
268 3-phosphoethanolamine may affect lower-airway microbiome composition and  
269 respiratory health in preterm infants. Our findings also identified a significant positive

270 correlation between the abundance of *Stenotrophomonas* and sn-glycerol  
271 3-phosphoethanolamine levels, an association that was confirmed with the KEGG  
272 database. This indicates that *Stenotrophomonas* may be abundant in the lower-airway  
273 microbiome of infants with BPD and responsible for the production of sn-glycerol  
274 3-phosphoethanolamine, which may act as a pathogenic signal in these patients.

275 To the author's knowledge, this prospective study is the first to identify a  
276 microbiome-metabolome signature in preterm infants with BPD. However, this study  
277 had several limitations. First, the sample size was small. Second, the data did not  
278 provide evidence that the lower-airway microbiome directly contributed to BPD.  
279 Although it will be challenging to determine a causal relationship between the  
280 lower-airway microbiome, metabolites and BPD development, further investigations  
281 are warranted.

282 In summary, there were significant differences in the diversity and composition  
283 of the lower-airway microbiome and metabolome in preterm infants with severe,  
284 moderate, or mild BPD or no BPD; the differences were more pronounced at birth  
285 (Day 1) than on Day 7 of life. Decreased diversity of the lower-airway microbiome,  
286 increased abundance of *Stenotrophomonas*, and increased level of sn-glycerol  
287 3-phosphoethanolamine were positively associated with BPD severity, and have  
288 potential as predictive biomarkers for BPD. *Stenotrophomonas* may contribute to the  
289 development of BPD and influence the composition of the lower-airway microbiome  
290 through its metabolite, sn-glycerol 3-phosphoethanolamine. These findings provide  
291 novel insights into the lower-airway microbiome and its functions in BPD.

292  
293 **Funding:** National Natural Science Foundation of China Fund Project (No. 81571483,  
294 81971431), Shenzhen Science and Technology Innovation Free Exploration Project  
295 (JCYJ20170817100735621), Shenzhen Synthetic Biology Innovation Research  
296 Institute, Chinese Academy of Sciences, Opening to the Outside World Fund Project  
297 (DWKF20190008), Scientific Research Fund of Shenzhen University General  
298 Hospital (SUGH2020QD003).

299

300 **Competing interests:** There are no ethical/legal or financial conflicts involved in the  
301 article.

302

### 303 **References:**

- 304 [1] Onland W, Cools F, Kroon A, et al. Effect of Hydrocortisone Therapy Initiated 7 to 14 Days  
305 After Birth on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants  
306 Receiving Mechanical Ventilation: A Randomized Clinical Trial [J]. JAMA, 2019, 321(4):  
307 354-363.
- 308 [2] Erik A. Jensen MM, Kevin Dysart, MD1, Marie G. Gantz, PhD2, Scott McDonald BS2, Nicolas A.  
309 Bamat, MD MSCE1, Martin Keszler, MD3; Haresh Kirpalani, BM MSc1; Matthew M. Laughon,  
310 MD MPH4; Brenda B. Poindexter, MD MS5; Andrea F. Duncan, MD MS6; Bradley A. Yoder,  
311 MD7; Eric C. Eichenwald, MD1, Sara B. DeMauro, MD MSCE. The Diagnosis of  
312 Bronchopulmonary Dysplasia in Very Preterm Infants: An Evidence-Based Approach [J]. Am J  
313 Respir Crit Care Med, 2019, doi: 10.1164/rccm.201812-2348OC(
- 314 [3] Bradley Wallace M, Amelie Peisl, BS,, Gregory Seedorf B, Taylor Nowlin, BS, Christina Kim, MD,  
315 Jennifer Bosco, PhD, Jon Kenniston, PhD, Dennis Keefe, PhD, and Steven H. Abman M.  
316 Anti-sFlt-1 Therapy Preserves Lung Alveolar and Vascular Growth in Antenatal Models of BPD  
317 [J]. American journal of respiratory and critical care medicine, 2018, 197(6): 776-787.
- 318 [4] Remot A, Descamps D, Noordine ML, et al. Bacteria isolated from lung modulate asthma  
319 susceptibility in mice [J]. ISME J, 2017, 11(5): 1061-1074.
- 320 [5] Pammi M, Lal CV, Wagner BD, et al. Airway Microbiome and Development of  
321 Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review [J]. J Pediatr, 2019,  
322 204(126-133 e122.
- 323 [6] Francisco Casado REM. The emergence of preclinical studies on the role of the microbiome in  
324 lung development and experimental animal models of bronchopulmonary dysplasia [J]. Am J  
325 Physiol Lung Cell Mol Physiol, 2020,
- 326 [7] Ubags NDJ and Marsland BJ. Mechanistic insight into the function of the microbiome in lung  
327 diseases [J]. Eur Respir J, 2017, 50(3):
- 328 [8] Tracy M, Cogen J and Hoffman LR. The pediatric microbiome and the lung [J]. Curr Opin  
329 Pediatr, 2015, 27(3): 348-355.
- 330 [9] Lal CV, Travers C, Aghai ZH, et al. The Airway Microbiome at Birth [J]. Sci Rep, 2016, 6(31023.
- 331 [10] Wagner BD, Sontag MK, Harris JK, et al. Airway Microbial Community Turnover Differs by BPD  
332 Severity in Ventilated Preterm Infants [J]. PLoS One, 2017, 12(1): e0170120.
- 333 [11] Vojinovic D, Radjabzadeh D, Kurilshikov A, et al. Relationship between gut microbiota and  
334 circulating metabolites in population-based cohorts [J]. Nat Commun, 2019, 10(1): 5813.
- 335 [12] Kjellberg M, Bjorkman K, Rohdin M, et al. Bronchopulmonary dysplasia: clinical grading in  
336 relation to ventilation/perfusion mismatch measured by single photon emission computed  
337 tomography [J]. Pediatr Pulmonol, 2013, 48(12): 1206-1213.
- 338 [13] BANCALARI AHJaE. Bronchopulmonary Dysplasia [J]. American journal of respiratory and  
339 critical care medicine, 2001, 163(7): 1723-1729.
- 340 [14] Lohmann P, Luna RA, Hollister EB, et al. The airway microbiome of intubated premature  
341 infants: characteristics and changes that predict the development of bronchopulmonary

dysplasia [J]. *Pediatr Res*, 2014, 76(3): 294-301.

[15] Mourani PM, Harris JK, Sontag MK, et al. Molecular identification of bacteria in tracheal aspirate fluid from mechanically ventilated preterm infants [J]. *PLoS One*, 2011, 6(10): e25959.

[16] Lu K, Abo RP, Schlieper KA, et al. Arsenic exposure perturbs the gut microbiome and its metabolic profile in mice: an integrated metagenomics and metabolomics analysis [J]. *Environ Health Perspect*, 2014, 122(3): 284-291.

[17] Ryan RP, Monchy S, Cardinale M, et al. The versatility and adaptation of bacteria from the genus *Stenotrophomonas* [J]. *Nat Rev Microbiol*, 2009, 7(7): 514-525.

[18] An SQ and Berg G. *Stenotrophomonas maltophilia* [J]. *Trends Microbiol*, 2018, 26(7): 637-638.

[19] David Skurnik1; Michael R. Davis JDBKLMCCDRDCTRLWTM-L, Vargas5; CCRHTRMELT50 and Alexander J. McAdam6; Tami D. Lieberman7; Roy Kishony7 JLL, 10; Gerald B. Pier; Joanna B. Goldberg2; Gregory P. Priebe1,3. Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection [J]. *Journal of Infectious Diseases*, 2012, 205(11): 1709-1718.

[20] Lisa C Crossman VCG, J Maxwell Dow, Georgios S Vernikos, Aki Okazaki, Mohammed Sebahia, David Saunders, Claire Arrowsmith, Tim Carver, Nicholas Peters, Ellen Adlem, Arnaud Kerhornou, Angela Lord, Lee Murphy, Katharine Seeger, Robert Squares, Simon Rutter, Michael A Quail, MariAdele Rajandream, David Harris, Carol Churcher, Stephen D Bentley, Julian Parkhill, Nicholas R Thomson and Matthew B Avison. The complete genome, comparative and functional analysis of *Stenotrophomonas maltophilia* reveals an organism heavily shielded by drug resistance determinants [J]. *Genome Biology*, 2008, 9(4): 2893-2905.

[21] Reshma Amin VW. Antibiotic treatment for *Stenotrophomonas maltophilia* in people with cystic fibrosis [J]. *TheCochrane Library*, 2012, 5.

[22] Watson L, Esterly J, Jensen AO, et al. Sulfamethoxazole/trimethoprim versus fluoroquinolones for the treatment of *Stenotrophomonas maltophilia* bloodstream infections [J]. *J Glob Antimicrob Resist*, 2018, 12(104-106).

[23] Liu W, Russel J, Roder HL, et al. Low-abundant species facilitates specific spatial organization that promotes multispecies biofilm formation [J]. *Environ Microbiol*, 2017, 19(7): 2893-2905.

[24] Liu W, Russel J, Burmolle M, et al. Micro-scale intermixing: a requisite for stable and synergistic co-establishment in a four-species biofilm [J]. *ISME J*, 2018, 12(8): 1940-1951.

[25] Blutt SE and Estes MK. Gut Bacterial Bouncers: Keeping Viral Pathogens out of the Epithelium [J]. *Cell Host Microbe*, 2019, 26(5): 569-570.

[26] Olin A, Henckel E, Chen Y, et al. Stereotypic Immune System Development in Newborn Children [J]. *Cell*, 2018, 174(5): 1277-1292 e1214.

[27] Liu R, Hong J, Xu X, et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention [J]. *Nat Med*, 2017, 23(7): 859-868.

[28] Kondakova T, D'Heygere F, Feuilloley MJ, et al. Glycerophospholipid synthesis and functions in *Pseudomonas* [J]. *Chem Phys Lipids*, 2015, 190(27-42).

[29] Fang W, Li C, Wu Q, et al. Metabolic profiling of chronic obstructive pulmonary disease model rats and the interventional effects of HuaTanJiangQi decoction using UHPLC-Q-TOF/MS(E) [J]. *J Pharm Biomed Anal*, 2020, 180(113078).


[30] Loering S, Cameron GJM, Starkey MR, et al. Lung development and emerging roles for type 2 immunity [J]. *J Pathol*, 2019, 247(5): 686-696.

- 386 [31] Balany J and Bhandari V. Understanding the Impact of Infection, Inflammation, and Their  
387 Persistence in the Pathogenesis of Bronchopulmonary Dysplasia [J]. Front Med (Lausanne),  
388 2015, 2(90).  
389 [32] Wang X-H, Jia H-L, Deng L, et al. Astragalus polysaccharides mediated preventive effects on  
390 bronchopulmonary dysplasia in rats [J]. Pediatric Research, 2014, 76(4): 347-354.  
391

**Table 1 Demographic and clinical characteristics of the included patients**

	<b>Severe BPD group (n=10)</b>	<b>moderate BPD group (n=5)</b>	<b>mild BPD group (n=10)</b>	<b>control group (n=5)</b>	<b>P value</b>
Gestational Age (mean $\pm$ SD)	30.46 $\pm$ 2.18	32.54 $\pm$ 1.35	31.76 $\pm$ 1.54	31.57 $\pm$ 0.61	0.138
Birth weight (g) (mean $\pm$ SD)	1396.6 $\pm$ 373.00	1530.0 $\pm$ 363.67	1574 $\pm$ 211.72	1640 $\pm$ 139.10	0.421
1 $\square$ min Apgar(mean $\pm$ SD)	5.44 $\pm$ 3.05	5.00 $\pm$ 4.06	5.4 $\pm$ 2.71	7.00 $\pm$ 2.24	0.720
5 $\square$ min Apgar (median)	8(8-9)	8(7-9)	8.5(5-10)	9(8-9)	0.819
10 $\square$ min Apgar (median)	9(8-9)	8(8-9)	9(8-10)	10(9-10)	0.148
Male Gender n (%)	5(50%)	4(80%)	4(40%)	1(20%)	0.274
Han population, n (%)	10(100%)	4(80%)	10(100%)	5(100%)	0.160
Cesarean delivery, n (%)	5(50%)	5(100%)	8(80%)	5(100%)	0.069
Antenatal steroids, n(%)	7(70%)	2(40%)	7(70%)	3(60%)	0.664
Rupture of membranes> 18 hours, n (%)	1(10%)	1(20%)	1(10%)	1(20%)	0.902
Intrauterine growth restriction, n (%)	1(10%)	1(20%)	0(0%)	0(0%)	0.444
Treatment with surfactant, n (%)	7(30%)	2(40%)	8(80%)	3(60%)	0.466
Mechanical Ventilation hours (median)	608	222	265	144	<b>0.003</b>
Oxygen days	6(0-36)	11(7-23)	14.5(12-20)	11(9-18)	0.720
Antibiotic days (median)	39	16	23	14	<b>0.011</b>
Pneumonia, n (%)	10(100%)	5(100%)	9(90%)	5(100%)	0.558
Pulmonary hemorrhage, n (%)	5(50%)	2(40%)	3(30%)	0(0%)	0.272
Late onset sepsis, n (%)	5(50%)	0(0%)	5(50%)	1(20%)	0.170
Necrotizing	0(0%)	0(0%)	1(10%)	0(0%)	0.558


enterocolitis≥					
stage 2, n (%)					



**Figure 1 Diversity and composition of the lower-airway microbiome**

(a) Shannon index at birth (Day 1); (b) Shannon index on Day 7 after birth (a greater Shannon index is indicative of higher microbial diversity); (c) Principal coordinate analysis (PCoA) of microbial communities at birth (Day 1) (d) PCoA of microbial communities on Day 7 after birth (samples located close to each other have similar microbial compositions, samples at distant locations have distinct microbial compositions); (e-f) Relative abundance of bacterial phyla (birth [Day 1], e; 7 days after birth, f) . (g-h) Relative abundance of bacterial genera (birth [Day 1], g; 7 days


after birth, h). (A, severe BPD [n=10]; B, moderate BPD [n=5]; C, mild BPD [n=10]; D, no BPD [n=5]).



**Figure 2 Abundance of *Stenotrophomonas***


(a) The abundance of *Stenotrophomonas* at birth (Day 1),  $P < 0.05$ ; (b) the abundance of *Stenotrophomonas* on Day 7 after birth,  $P=0.064$ . (A, severe BPD [n=10]; B, moderate BPD [n=5]; C, mild BPD [n=10]; D, no BPD [n=5]).






**Figure 3: Metabolic profiles**

(a-b) Principal Component Analysis (PCA) based on the metabolic profiles in sputum samples (birth [Day 1], a; 7 days after birth, b); (c-f) Hierarchical clustering heat maps showing patterns in molecular data across groups. The relative amounts of the 86 compounds were transformed into Z scores (birth [Day 1] ES-, c; ES+, d; 7 days after birth ES-, e, ES+, f). (A, severe BPD [n=10]; B, moderate BPD [n=5]; C, mild BPD [n=10]; D, no BPD [n=5]). ES+: positive ion mode, ES-: negative ion mode)



**Figure 4: sn-Glycerol 3-phosphoethanolamine level at birth (Day 1)**

\*: $P < 0.05$ .



**Figure 5: Scatter plot of the association between abundance of *Stenotrophomonas* and sn-glycerol 3-phosphoethanolamine level**  
 $r=0.45$ ,  $P<0.05$ .